28316031|t|Transactivation Domain of Human c-Myc Is Essential to Alleviate Poly(Q) -Mediated Neurotoxicity in Drosophila Disease Models
28316031|a|Polyglutamine (poly(Q)) disorders, such as Huntington's disease (HD) and spinocerebellar ataxias, represent a group of neurological disorders which arise due to an atypically expanded poly(Q) tract in the coding region of the affected gene. Pathogenesis of these disorders inside the cells begins with the assembly of these mutant proteins in the form of insoluble inclusion bodies (IBs), which progressively sequester several vital cellular transcription factors and other essential proteins, and finally leads to neuronal dysfunction and apoptosis. We have shown earlier that targeted upregulation of Drosophila myc (dmyc) dominantly suppresses the poly(Q) toxicity in Drosophila. The present study examines the ability of the human c-myc proto-oncogene and also identifies the specific c-Myc isoform which drives the mitigation of poly(Q) -mediated neurotoxicity, so that it could be further substantiated as a potential drug target. We report for the first time that similar to dmyc, tissue-specific induced expression of human c-myc also suppresses poly(Q) -mediated neurotoxicity by an analogous mechanism. Among the three isoforms of c-Myc, the rescue potential was maximally manifested by the full-length c-Myc2 protein, followed by c-Myc1, but not by c-MycS which lacks the transactivation domain. Our study suggests that strategies focussing on the transactivation domain of c-Myc could be a very useful approach to design novel drug molecules against poly(Q) disorders.
28316031	0	15	Transactivation	T045	C0040624
28316031	16	22	Domain	T087	C1514562
28316031	26	37	Human c-Myc	T116,T123	C1454487
28316031	64	71	Poly(Q)	T116	C0384782
28316031	82	95	Neurotoxicity	T037	C0235032
28316031	99	109	Drosophila	T204	C0013138
28316031	110	124	Disease Models	T050	C0684309
28316031	125	138	Polyglutamine	T116	C0384782
28316031	140	147	poly(Q)	T116	C0384782
28316031	149	158	disorders	T047	C0012634
28316031	168	188	Huntington's disease	T047	C0020179
28316031	190	192	HD	T047	C0020179
28316031	198	221	spinocerebellar ataxias	T047	C0087012
28316031	244	266	neurological disorders	T047	C0027765
28316031	300	308	expanded	T082	C0205229
28316031	309	316	poly(Q)	T116	C0384782
28316031	330	343	coding region	T028	C0079941
28316031	360	364	gene	T028	C0017337
28316031	366	378	Pathogenesis	T046	C0699748
28316031	388	397	disorders	T047	C0012634
28316031	409	414	cells	T025	C0007634
28316031	449	464	mutant proteins	T116	C1564139
28316031	490	506	inclusion bodies	T026	C0007637
28316031	508	511	IBs	T026	C0007637
28316031	558	566	cellular	T025	C0007634
28316031	567	588	transcription factors	T116,T123	C0040648
28316031	599	608	essential	T080	C0205224
28316031	609	617	proteins	T116,T123	C0033684
28316031	640	648	neuronal	T025	C0027882
28316031	649	660	dysfunction	T077	C3887504
28316031	665	674	apoptosis	T043	C0162638
28316031	703	711	targeted	T169	C1521840
28316031	712	724	upregulation	T044	C0041904
28316031	728	742	Drosophila myc	T116,T123	C1317967
28316031	744	748	dmyc	T116,T123	C1317967
28316031	776	783	poly(Q)	T116	C0384782
28316031	784	792	toxicity	T037	C0600688
28316031	796	806	Drosophila	T204	C0013138
28316031	854	880	human c-myc proto-oncogene	T116,T123	C1454487
28316031	914	919	c-Myc	T116,T123	C1454487
28316031	920	927	isoform	T116	C0597298
28316031	959	966	poly(Q)	T116	C0384782
28316031	977	990	neurotoxicity	T037	C0235032
28316031	1039	1048	potential	T080	C3245505
28316031	1049	1053	drug	T121	C1254351
28316031	1054	1060	target	T169	C1521840
28316031	1107	1111	dmyc	T116,T123	C1317967
28316031	1113	1128	tissue-specific	T024	C1955394
28316031	1129	1147	induced expression	T045	C1171362
28316031	1151	1162	human c-myc	T116,T123	C1454487
28316031	1168	1178	suppresses	T169	C1260953
28316031	1179	1186	poly(Q)	T116	C0384782
28316031	1197	1210	neurotoxicity	T037	C0235032
28316031	1217	1236	analogous mechanism	T169	C0441712
28316031	1254	1262	isoforms	T116	C0597298
28316031	1266	1271	c-Myc	T116,T123	C1454487
28316031	1284	1293	potential	T080	C3245505
28316031	1338	1352	c-Myc2 protein	T116,T123	C1454487
28316031	1366	1372	c-Myc1	T116,T123	C1454487
28316031	1385	1391	c-MycS	T116,T123	C1454487
28316031	1408	1423	transactivation	T045	C0040624
28316031	1424	1430	domain	T087	C1514562
28316031	1484	1499	transactivation	T045	C0040624
28316031	1500	1506	domain	T087	C1514562
28316031	1510	1515	c-Myc	T116,T123	C1454487
28316031	1564	1578	drug molecules	T121	C1254351
28316031	1587	1594	poly(Q)	T116	C0384782
28316031	1595	1604	disorders	T047	C0012634